1. Home
  2. PNNT vs STOK Comparison

PNNT vs STOK Comparison

Compare PNNT & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PNNT
  • STOK
  • Stock Information
  • Founded
  • PNNT 2007
  • STOK 2014
  • Country
  • PNNT United States
  • STOK United States
  • Employees
  • PNNT N/A
  • STOK N/A
  • Industry
  • PNNT Finance: Consumer Services
  • STOK Biotechnology: Pharmaceutical Preparations
  • Sector
  • PNNT Finance
  • STOK Health Care
  • Exchange
  • PNNT Nasdaq
  • STOK Nasdaq
  • Market Cap
  • PNNT 462.3M
  • STOK 517.0M
  • IPO Year
  • PNNT 2007
  • STOK 2019
  • Fundamental
  • Price
  • PNNT $6.85
  • STOK $9.05
  • Analyst Decision
  • PNNT Hold
  • STOK Strong Buy
  • Analyst Count
  • PNNT 3
  • STOK 5
  • Target Price
  • PNNT $6.00
  • STOK $27.50
  • AVG Volume (30 Days)
  • PNNT 447.0K
  • STOK 792.0K
  • Earning Date
  • PNNT 05-12-2025
  • STOK 05-13-2025
  • Dividend Yield
  • PNNT 13.99%
  • STOK N/A
  • EPS Growth
  • PNNT N/A
  • STOK N/A
  • EPS
  • PNNT 0.73
  • STOK 0.88
  • Revenue
  • PNNT $138,371,000.00
  • STOK $190,908,000.00
  • Revenue This Year
  • PNNT N/A
  • STOK $27.80
  • Revenue Next Year
  • PNNT N/A
  • STOK $9.53
  • P/E Ratio
  • PNNT $9.41
  • STOK $10.11
  • Revenue Growth
  • PNNT N/A
  • STOK 2333.81
  • 52 Week Low
  • PNNT $5.72
  • STOK $5.35
  • 52 Week High
  • PNNT $8.04
  • STOK $17.58
  • Technical
  • Relative Strength Index (RSI)
  • PNNT 59.10
  • STOK 51.53
  • Support Level
  • PNNT $6.46
  • STOK $8.30
  • Resistance Level
  • PNNT $6.98
  • STOK $10.12
  • Average True Range (ATR)
  • PNNT 0.17
  • STOK 0.65
  • MACD
  • PNNT 0.06
  • STOK -0.05
  • Stochastic Oscillator
  • PNNT 71.88
  • STOK 29.44

About PNNT PennantPark Investment Corporation

Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: